| DB ID | MyCo_3236 |
| Title | Performance of 1,3-beta-D-glucan in the diagnosis and monitoring of invasive fusariosis |
| Year | 2019 |
| PMID | 31025423 |
| Fungal Diseases involved | Invasive fusariosis |
| Associated Medical Condition | None |
| Genus | Fusarium |
| Species | oxysporum |
| Organism | Fusarium oxysporum species complex |
| Ethical Statement | The study was approved by the local ethical committee (“Comitê de Ética em Pesquisa do Hospital Universitário Clementino Fraga Filho,” protocol number 077‐16), with a waiver of the need for written informed consent, because of the observational nature of the study. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | This is a retrospective study conducted at University Hospital, Federal University of Rio de Janeiro. Beginning in March 2008, all haematologic patients at risk to develop invasive aspergillosis had serial (2‐3 times per week) serum samples collected for galactoman-nan testing. During the study period, 17 cases of invasive fusariosis were diagnosed among 639 episodes of febrile neutropenia (2.7%). |
| Cohort No. | 17 |
| Age Group | 18‐64 |
| P Value | p=0.04 |
| Sensitivity | 0.85 |
| Specificity | 0.69 |
| Positive Predictive Value | 0.07 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fusariosis is an important invasive fungal disease (IFD) in haematologic patients worldwide, and is one of the most frequent IFDs in Brazilian haematologic centres. The disease presents typically with metastatic skin lesions and positive blood cultures, reflecting a high fungal burden at diagnosis. We have previously reported a series of 15 out of 18 patients with invasive fusariosis who presented with positive serum galactomannan. The test was positive before the first clinical manifestation of fusariosis in the majority of cases, suggesting that a fungal biomarker could be of help in establishing the diagnosis of invasive fusariosis at an earlier disease stage. |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
